Our study hints that inhibiting TXNRD1 activated Nrf2/HO-1 signaling and alleviated oxidation stress and inflammation, which can be a promising therapy target of COPD. The gene discussed is TXNRD1; the disease is chronic obstructive pulmonary disease.